Abstract |
VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.
|
Authors | John M L Ebos, Roberto Pili |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 18
Issue 14
Pg. 3719-21
(Jul 15 2012)
ISSN: 1557-3265 [Electronic] United States |
PMID | 22679177
(Publication Type: Journal Article)
|
Chemical References |
- Vascular Endothelial Growth Factor A
|
Topics |
- Animals
- Cell Proliferation
- Clinical Trials as Topic
- Endothelial Cells
(cytology)
- Humans
- Mice
- Neoplasms
(therapy)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
|